Literature DB >> 17431897

Pituitary abnormalities in Prader-Willi syndrome and early onset morbid obesity.

Jennifer L Miller1, Anthony P Goldstone, Jessica A Couch, Jonathan Shuster, Guojun He, Daniel J Driscoll, Yijun Liu, Ilona M Schmalfuss.   

Abstract

Prader-Willi syndrome (PWS) is a well-defined syndrome of childhood-obesity which can serve as a model for investigating early onset childhood obesity. Many of the clinical features of PWS (e.g., hyperphagia, hypogonadotropic hypogonadism, growth hormone deficiency) are hypothesized to be due to abnormalities of the hypothalamus and/or pituitary gland. Children who become severely obese very early in life (i.e., before age 4 years) may also have a genetic etiology of their obesity, perhaps with associated neuroendocrine and hypothalamo-pituitary defects, as infants and very young children have limited access to environmental factors that contribute to obesity. We hypothesized that morphologic abnormalities of the pituitary gland would be seen in both individuals with PWS and other subjects with early onset morbid obesity (EMO). This case-control study included individuals with PWS (n = 27, age 3 months to 39 years), patients with EMO of unknown etiology (n = 16, age 4-22 years; defined as body mass index greater than the 97th centile for age before age 4 years), and normal weight siblings (n = 25, age 7 months to 43 years) from both groups. Participants had 3-dimensional magnetic resonance imaging to evaluate the pituitary gland, a complete history and physical examination, and measurement of basal pituitary hormones. Subjects with PWS and EMO had a higher prevalence of pituitary morphological abnormalities than did control subjects (74% PWS, 69% EMO, 8% controls; P < 0.001). Anterior pituitary hormone deficiencies were universal in individuals with PWS (low IGF-1 in 100%, P < 0.001 PWS vs. controls; central hypothyroidism in 19%, P = 0.052, and hypoplastic genitalia or hypogonadotropic hypogonadism in 100%, P < 0.001), and was often seen in individuals with EMO (6%, P = 0.89 vs. control, 31%, P = 0.002, and 25%, P = 0.018, respectively). The presence of a hypoplastic pituitary gland appeared to correlate with the presence of anterior pituitary hormone deficiencies in individuals with EMO, but no correlation was apparent in individuals with PWS. In conclusion, the high frequency of both morphological and hormonal abnormalities of the pituitary gland in both individuals with PWS and EMO suggests that abnormalities in the hypothalamo-pituitary axis are features not only of PWS, but also frequently of EMO of unknown etiology. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 17431897     DOI: 10.1002/ajmg.a.31677

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  20 in total

Review 1.  A Narrative Review of Medical and Genetic Risk Factors among Children Age 5 and Younger with Severe Obesity.

Authors:  Nazrat Mirza; Thao-Ly Phan; June Tester; Angela Fals; Cristina Fernandez; George Datto; Elizabeth Estrada; Ihuoma Eneli
Journal:  Child Obes       Date:  2018-05-23       Impact factor: 2.992

Review 2.  Review of Prader-Willi syndrome: the endocrine approach.

Authors:  Ryan Heksch; Manmohan Kamboj; Kathryn Anglin; Kathryn Obrynba
Journal:  Transl Pediatr       Date:  2017-10

3.  Approach to the child with prader-willi syndrome.

Authors:  Jennifer L Miller
Journal:  J Clin Endocrinol Metab       Date:  2012-11       Impact factor: 5.958

4.  Global deficits in development, function, and gene expression in the endocrine pancreas in a deletion mouse model of Prader-Willi syndrome.

Authors:  Mihaela Stefan; Rebecca A Simmons; Suzanne Bertera; Massimo Trucco; Farzad Esni; Peter Drain; Robert D Nicholls
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-02-22       Impact factor: 4.310

Review 5.  Prader-Willi, Angelman, and 15q11-q13 Duplication Syndromes.

Authors:  Louisa Kalsner; Stormy J Chamberlain
Journal:  Pediatr Clin North Am       Date:  2015-04-22       Impact factor: 3.278

6.  Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome.

Authors:  Roja Motaghedi; Elizabeth G Lipman; Jeannette E Hogg; Paul J Christos; Maria G Vogiatzi; Moris A Angulo
Journal:  Eur J Med Genet       Date:  2010-10-20       Impact factor: 2.708

7.  Impaired hypothalamic regulation of endocrine function and delayed counterregulatory response to hypoglycemia in Magel2-null mice.

Authors:  Alysa A Tennese; Rachel Wevrick
Journal:  Endocrinology       Date:  2011-01-19       Impact factor: 4.736

Review 8.  Prader- Willi syndrome: An uptodate on endocrine and metabolic complications.

Authors:  Giovanna Muscogiuri; Gloria Formoso; Gabriella Pugliese; Rosaria Maddalena Ruggeri; Elisabetta Scarano; Annamaria Colao
Journal:  Rev Endocr Metab Disord       Date:  2019-06       Impact factor: 6.514

9.  Central precocious puberty and growth hormone deficiency in a boy with Prader-Willi syndrome.

Authors:  Antonino Crinò; Girolamo Di Giorgio; Riccardo Schiaffini; Alessandra Fierabracci; Sabrina Spera; Andrea Maggioni; Guido Castelli Gattinara
Journal:  Eur J Pediatr       Date:  2008-02-27       Impact factor: 3.183

10.  Neural correlates to food-related behavior in normal-weight and overweight/obese participants.

Authors:  Alan Ho; James Kennedy; Anastasia Dimitropoulos
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.